Buy or sell Humacyte stock pre IPO via an EquityZen fund

EquityZen is a marketplace for shares of proven pre IPO tech companies

Humacyte Stock

Biotechnology

Founded

2004

Notable Investors

California Institute for Regenerative Medicine

Headquarters

Morrisville NC, US

Total Funding

$468M

About Humacyte Stock

Humacyte, Inc. develops products for vascular disease and replacement of anatomical conduits. It offers human tissue-based products for regenerative medicine and vascular surgery applications; off-the-shelf extracellular matrix tissue products, which are formed in vitro from banked vascular smooth muscle cells and then decellularized to eliminate the risk of rejection; and vascular grafts. The company was incorporated in 2004 and is headquartered in Morrisville, North Carolina.

Investors

Bangkok bank

Humacyte

California Institute for Regenerative Medicine

Humacyte

Pacific Eagle Asset Management

Humacyte

Funding History

November 2009$7.0M
September 2010$12.0M
January 2015$49.8M
October 2015$150M
August 2016$10.0M
September 2017$14.1M
March 2018$75.0M
June 2018$150M

Management

Chief Executive Officer

Jeffrey Lawson

Co-Founder & Executive Vice President, Strategic Business Operations

Julianna Blum

Chief Financial Officer

Douglas Blankenship

Press

Other Companies

EquityZen does not have an affiliation with, formal relationship with, or endorsement from Humacyte or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 100K+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

LogoLogo